ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market

Zimmer Biomet Holdings, Inc. ZBH posted second-quarter 2026 adjusted earnings per share of $2.07, which beat the Zacks Consensus Estimate of $2.01 by 2.99%. The adjusted figure was unchanged year over year.

The quarter’s adjustments included intangible asset amortization, restructuring and other cost-reduction initiatives, inventory and manufacturing-related charges, acquisition and integration costs, litigation expenses and other charges.

GAAP earnings were $1.03 per share compared with 77 cents in the year-ago period.

ZBH's Revenues

Net sales of $2.18 billion increased 4.8% year over year. The figure also surpassed the Zacks Consensus Estimate of $2.13 billion by 2.25%.

Sales increased 4.7% on a constant-currency basis and 4% on an organic constant-currency basis. The organic measure excludes the impact of the Paragon 28 acquisition.

Following the earnings announcement, ZBH stock rose 1.4% in pre-market trading today.

ZBH's Revenues by Geography

Sales generated in the United States totaled $1.24 billion, up 5.6% year over year.

International sales grossed $937 million, reflecting growth of 3.7% on a reported basis and 3.5% on a constant currency basis.

Zimmer Biomet Holdings, Inc. Price, Consensus and EPS Surprise

Zimmer Biomet Holdings, Inc. price-consensus-eps-surprise-chart | Zimmer Biomet Holdings, Inc. Quote

Segmental Analysis of ZBH's Revenues

The company currently reports under four product categories: Knees, Hips, S.E.T. and Technology & Data, Bone Cement and Surgical.

Sales in the Knees unit improved 0.4% year over year to $828.9 million. At constant exchange rate or CER, revenues increased 0.1%. U.S. Knees sales rose 1.4%, while international sales declined 0.9% on a reported basis and 1.5% at CER.

Hipssales increased 5% year over year to $562.7 million and rose 5.1% at CER. U.S. Hips revenues advanced 5.9%, while international sales grew 4% on a reported basis and 4.2% at CER.

Revenues in the S.E.T. unit, comprising Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic, rose 6.4% year over year to $586 million. Sales increased 6.2% at CER.

Technology & Data, Bone Cement and Surgicalrevenues surged 21.1% to $199.4 million. At CER, sales increased 21.5%, marking the strongest growth among Zimmer Biomet’s product categories.

ZBH's Margin Performance

Adjusted gross margin, after excluding intangible asset amortization and inventory and manufacturing-related charges, was 71.1%. This compared with approximately 72.3% in the year-ago quarter.

Cost of products sold, excluding intangible asset amortization, increased 7.3% to $635.5 million. Selling, general and administrative expenses rose 10.4% to $899.3 million, while research and development expenses declined 7.5% to $104.8 million.

Adjusted operating profit was $559.7 million compared with $578.5 million a year earlier. The adjusted operating margin contracted 210 basis points to 25.7%.

ZBH's Cash Position

Zimmer Biomet exited the second quarter of 2026 with cash and cash equivalents of $410 million compared with $591.9 million at the end of 2025.

Net cash provided by operating activities was $447.9 million in the quarter compared with $378.2 million in the year-ago period. Free cash flow increased to $308.3 million from $247.7 million.

For the first six months of 2026, operating cash flow totaled $807.2 million. The company repurchased $500.8 million of common stock and paid $93.4 million in dividends during the period.

ZBH's 2026 Guidance Raised

Zimmer Biomet updated its financial guidance for 2026. Reported revenue growth is now expected in the range of 3.9-4.9%, up from the prior projection of 2.5-4.5%. The Zacks Consensus Estimate for 2026 revenues is currently pegged at $8.53 billion.

Constant-currency revenue growth is projected between 3.4% and 4.4%, compared with the earlier range of 2-4%. Organic constant-currency growth is expected in the band of 2.25-3.25%, up from 1-3%.

Adjusted earnings for the full year are now expected in the range of $8.47-$8.59 per share. The previous guidance called for adjusted earnings of $8.40-$8.55. The Zacks Consensus Estimate for 2026 adjusted earnings is currently pegged at $8.48 per share.

Our Take on ZBH

Zimmer Biomet exited the second quarter with better-than-expected earnings and revenues. Growth in Hips, S.E.T. and Technology & Data, Bone Cement and Surgical offset the modest performance of the Knees category.

The strong expansion in Technology & Data, Bone Cement and Surgical sales was encouraging. Higher operating cash flow and free cash flow also supported the quarterly performance.

However, the contraction in adjusted gross and operating margins remains a concern. Rising product costs and selling, general and administrative expenses weighed on profitability despite revenue growth.

ZBH’s Zacks Rank & Key Picks

Zimmer Biomet currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Quest Diagnostics DGX and Medpace MEDP.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

ISRG has an earnings yield of 3.1% against the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.

Quest Diagnostics, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $3.12, exceeding the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion topped the Zacks Consensus Estimate by 2.1%.

DGX has an earnings yield of 4.7%, almost in line with the industry’s yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.77%.

Medpace, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 4.17%. Revenues of $707.3 million outperformed the consensus mark by 1.12%.

MEDP has a historical five-year earnings growth rate of 30.5% compared with the industry’s 5.6% growth. In the trailing four quarters, the company delivered an average earnings surprise of 10.16%.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research